Policy & Regulation
Immunexpress Names Rolland Carlson, Ph.D. as CEO
16 April 2018 - - Seattle, Washington-based molecular diagnostic company Immunexpress, Inc. has appointed Rolland D. Carlson, Ph.D. as chief executive officer, the company said.
In his new role, he assumes responsibility for the continued development and commercialization of the company's lead product, SeptiCyte, on the Idylla platform.
Carlson most recently served as president and CEO of WaferGen Biosystems. He has a wealth of experience navigating the domestic and international diagnostic regulatory space, raising both public and private capital, successfully commercializing products and engaging sales, marketing and business development teams.
Prior to WaferGen, Carlson was president and CEO of Asuragen, a privately-held molecular diagnostic company. Before that, he held increasingly senior positions at Abbott Laboratories over a 20-year period, including vice president and general manager of the Vysis molecular diagnostic business following its acquisition.
Carlson graduated with Ph.D. in Botany and Plant Physiology from Southern Illinois University and was a post-doctoral research fellow at the Harbor Branch Oceanographic Research Institute, Ft. Pierce, Florida.
Immunexpress is committed to improving outcomes for patients suspected of sepsis. The company's SeptiCyte technology rapidly quantifies, directly from whole blood, specific molecular markers from the patient's own immune system the 'host response'.
Its pipeline includes several assays for readily available instruments, including random access, point-of-care and sample-to-answer.


Related Headlines